COMP <GO>
OMER vs KRSA // EV/EBITDA & P/E VALUATION
Omeros Corporation (NASDAQ) VS. Korsana Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: OMER 1
— KRSA 4
■ METRIC PARITY
LAST: $18.95 (+5.98%) • MKT CAP: $1.37B
valuation
—
LAST: $30.22 (+0.37%) • MKT CAP: $1.38B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OMER VS. KRSA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OMER | KRSA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -5.70% | -29.30 | KRSA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.47% | -0.24% | -8.23 | KRSA | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 3.70% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | KRSA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.6 | 45.6 | +7.95 | OMER | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.37B | $1.38B | -$4.5M | KRSA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OMER REV | KRSA REV | OMER GROSS % | KRSA GROSS % | OMER FCF | KRSA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $2.1M | — | — | -$116.2M | -$3.3M |
| FY 2024 | $0 | $2.0M | — | — | -$149.0M | -$4.3M |
| FY 2023 | — | $0 | — | — | — | -$21.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OMER // BETA —
KRSA // BETA —